The search for value: Pharmacoeconomic issue in the treatment of depression

Journal of Practical Psychiatry and Behavioral Health

Volumn 2, Issue 1, 1996, Pages 2-13

  Burke, Michael J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Antidepressants; Clinical trials; Managed care; Pharmacoeconomics; Quality of life; Treatment effectiveness

Indexed keywords

EID: 0009704675     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Weiss B. Managed care: there's no stopping it now. Medical Economics 1995; (March): 26-13.
2. McFarland BH. Cost-effectiveness considerations for managed care systems: treating depression in primary care. Am J Med 1994;97(suppl 6A):47S-58S.
3. McGuire A, Hughes D. The economic evaluation of depression. Postgrad Med J 1994;70(suppl 2):S14-22.
4. Loewy EH. Cost should not be a factor in medical care. N Eng J Med 1980;302:697.
5. Health Care Finance Administration. US Dept of Health and Human Services. Health Care Financing Review, Fall 1994.
6. Mooney G. Cost-benefit analysis and medical ethics. J Med Ethics 1980;6:177-9.
7. Williams A. Cost-effectiveness analysis: is it ethical? J Med Ethics 1992;18(1):7-11.
8. Buxton MJ. Health economics in the 1990s. In: Jonsson B, Rosenbaum J, eds. Health economics of depression. New York: John Wiley and Sons; 1993:1-13.
9. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Eng J Med 1994;331:650-5.
10. Burke MJ, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom F, Kupfer D, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1994:1053-65.
11. Preskorn SH, Burke MJ. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992;53(9, suppl):5-18.
12. Ilstrup DM. Randomized clinical trials: potential cost savings due to the identification of ineffective medical therapies. Mayo Clin Proc 1995;70:707-10.
13. Cardiac Arrhythmia Suppression Trial. Preliminary report: effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Eng J Med 1989;321(6):406-12.
14. Jayasuriya A. Regulatory use and control of pharmacoeconomics. Presented at Methods and Applications for Pharmacoeconomic and Quality of Life Studies, Institute for International Research, Pharmaceutical and Health Care Division, San Francisco, CA, Nov. 16-18,1994.
15. Haskell L. Health economics related to pharmaceuticals in today's environment. Presented at New Frontiers in Pharmacoeconomic Research: Cost-effectiveness Research, Drug Information Association, Boston, MA, Dec. 13-4,1993.
16. DrummondMF, Brandt A, Luce BR, RoviraJ. Standardizing economic evaluation methodologies in health care. Int J Technology Assessment Health Care 1993;9(l):26-36.
17. Hillman A, Eisenberg J, Pauly M, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Eng J Med 1991;324(19):1362-5.
18. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analysis in the medical literature. Ann Intern Med 1992:116:238-44.
19. Lee JT, Sanchez LA. Interpretation of cost-effectiveness and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991;48:2622-7.
20. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analyses. N Eng J Med 1994;331(10):669-70.
21. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994;55(9, suppl A):42-52.
22. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995;273(l):59-65.
23. Jachuck SJ, Brierley H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982;32:103-4.
24. Rohrbaugh M, Rogers J. What did the doctor do? When physicians and patients disagree. Arch Fam Med 1994;3(2): 125-9.
25. Deber RB. Physicians in health care management: 7. the patient-physician partnership: changing roles and the desire for information. Can MedAssoc J 1994;151(2): 171-6.
26. Kramer MS, Etezadi-Amoli J, Ciampi A, et al. Parents' versus physicians' values for clinical outcomes in young febrile children. Pediatrics 1994;93(5):697-701.
27. Bech P, Dunbar GC, Stoker MJ. The challenge of measuring quality of life in psychiatric patients. In: Jonsson B, Rosenbaum J, eds. Health economics in depression. New York: John Wiley and Sons; 1993:111-28.
28. Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men: a comparison of captopril and enalapril. N EngJMed 1993;328:907-13.
29. Wells KB, Stewart A, Hays RD. The functioning and well-being of depressed patients: results of the Medical Outcomes Study. JAMA 1989;262:914-19.
30. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(6, suppl):60-9.
31. Katzelnick DJ, Kobak KA, Jefferson JW, Greist JH. Prescribing patterns of antidepressant medications for depression in a health care organization, 1993. Dean Foundation for Health, Research and Education. Poster session, NCDEU, 1995.
32. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:771.
33. Daly RJ. Suicide in depressed patients: medicolegal issues. Br J Psychiatry 1993;163(suppl 20):29-32.
34. Bickel ML. Poisoning by tricyclic antidepressants: general and pharmacokinetic considerations. Int J Clin Pharmacol 1975;11: 145-76.
35. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-73.
36. Boyer \VF, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum J, eds. Health economics of depression. New York: John Wiley and Sons; 1993:65-75.
37. Einarson T, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorder. Clin Ther 1995;17(l):136-53.
38. Nelson JC. Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatric Annals 1994;24(12): 628-31.
39. Sclar DA. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-39.
40. Calabrese D, Brixner D, Hildebrand M. Analysis of selective serotonin reuptake inhibitor utilization in a group model managed care setting. Presented at The Academy for Managed Care Pharmacy, Anaheim, CA, Oct. 1994.
41. Krupnick JL, Pincus HA. The cost-effectiveness of psychotherapy: a plan for research. Am J Psychiatry 1992;149(10):1295-1305.
42. Lieber AL. Managed-care and psychiatry. Clinical Psychiatry Quarterly 1995;18(2):6-7.
43. Sturm R, Wells K. How can care for depression become more cost-effective? JAMA 1995;273:51-8.